Who
Kimberly Blackwell
Director
Company insider
Files Form 4 as: Director, Monte Rosa Therapeutics; Director, Century Therapeutics; Chief Executive Officer, Zentalis Pharmaceuticals.
In numbers
- Trades disclosed
- 38
- Buys
- 1
- Sells
- 4
- Bought
- $51K
- Sold
- $324K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 1 Jul 2020
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $241K20,655 at $11.69 | filing |
| 13 Nov 2023filed 13 Nov 2023 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $51K5,000 at $10.29 | filing |
| 27 Jun 2023filed 29 Jun 2023 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,500 at $0.00 | filing |
| 1 Feb 2023filed 1 Feb 2023 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —355,200 at $0.00 | filing |
| 1 Feb 2023filed 1 Feb 2023 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —244,800 at $0.00 | filing |
| 15 Jun 2022filed 16 Jun 2022 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,872 at $0.00 | filing |
| 16 May 2022filed 20 May 2022 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,708,809 at $0.00 | filing |
| 16 May 2022filed 20 May 2022 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —427,202 at $0.00 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Kimberly Blackwell; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.